Phoenix、AZにおける転移性癌の臨床試験
Phoenixとその周辺地域（約30マイル以内）の拠点で、転移性癌に関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
被験者募集中第3相
- City of Hope, Phoenix
PRE-ISPY Phase I/II Oncology Platform Program
被験者募集中第1/2相
- Mayo Clinic Comprehensive Cancer Center, Phoenix
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
被験者募集中第2/3相
- Mayo Clinic Hospital, Phoenix
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
被験者募集中第3相
- Banner MD Anderson Cancer Center, Phoenix
- Ironwood Cancer & Research Centers, Phoenix
- Mayo Clinic Building- Phoenix, Phoenix
- 他1件
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
被験者募集中第1相
- Mayo Clinic Arizona, Phoenix
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
被験者募集中第2相
- Mayo Clinic Building-Phoenix, Phoenix
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
被験者募集中第2/3相
- Mayo Clinic Hospital, Phoenix
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Ironwood Cancer & Research Centers, Phoenix
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- HonorHealth, Phoenix
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
被験者募集中第2相
- Mayo Clinic Arizona, Phoenix
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
被験者募集中第1/2相
- Mayo Clinic Building- Phoenix, Phoenix
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Banner University Medical Center Phoenix, Phoenix
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Phoenix
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Mayo Clinic, Phoenix
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
被験者募集中第1/2相
- Crinetics Study Site, Phoenix
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Investigative Site #132, Phoenix
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
被験者募集中
- Dignity Health, Phoenix
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
被験者募集中観察研究
- Mayo Clinic in Arizona, Phoenix
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
被験者募集中第1/2相
- Mayo Clinic, Phoenix
他の都市における転移性癌の試験
- Houston, TX104件の研究
- New York City, NY93件の研究
- Nashville, TN70件の研究
- Boston, MA63件の研究
- Los Angeles, CA57件の研究
- St. Louis, MO54件の研究
- Arlington, VA53件の研究
- Philadelphia, PA46件の研究
- Chicago, IL45件の研究
- San Antonio, TX44件の研究
- Washington, DC43件の研究
- Dallas, TX42件の研究
Phoenixにおける他の研究
- 乳がん25件の研究
- 大腸癌25件の研究
- 肥満症22件の研究
- 非小細胞肺癌20件の研究
- 心不全18件の研究
- がん（全種類）17件の研究
- 前立腺がん17件の研究
- 心血管疾患16件の研究
- 多発性骨髄腫16件の研究
- 膵臓がん16件の研究
- 過体重15件の研究
- アルツハイマー病15件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。